Compare PEBO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | CMPX |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 926.7M |
| IPO Year | N/A | N/A |
| Metric | PEBO | CMPX |
|---|---|---|
| Price | $34.18 | $6.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $33.50 | $13.44 |
| AVG Volume (30 Days) | 370.5K | ★ 2.7M |
| Earning Date | 01-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | N/A |
| Revenue | ★ $417,146,000.00 | N/A |
| Revenue This Year | $17.29 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.21 | $1.33 |
| 52 Week High | $34.25 | $6.88 |
| Indicator | PEBO | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 68.11 | 61.78 |
| Support Level | $31.42 | $6.05 |
| Resistance Level | $34.25 | $6.88 |
| Average True Range (ATR) | 0.77 | 0.40 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 88.39 | 74.64 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.